NICM
APGE icon

Neo Ivy Capital Management’s Apogee Therapeutics APGE Stock Holding History

Neo Ivy Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,910
Closed -$823K – 333
2025
Q4 		$823K Buy
+10,910
New +$687K 0.13% 183
2025
Q1 		– Sell
-38,523
Closed -$1.75M – 283
2024
Q4 		$1.75M Buy
+38,523
New +$1.96M 0.35% 123

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Neo Ivy Capital Management's APGE Position: Q1 2026 in Review

Neo Ivy Capital Management sold out of Apogee Therapeutics (APGE) in Q1 2026, closing a stake of 10,910 shares — an estimated $823K sold.

Neo Ivy Capital Management first reported a position in APGE in Q4 2024 and held it in 2 quarters. The position peaked at $1.75M in Q4 2024. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Neo Ivy Capital Management reported no remaining Apogee Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Neo Ivy Capital Management sold 10,910 Apogee Therapeutics shares in Q1 2026, an estimated $823K.
  • Neo Ivy Capital Management first reported a position in Apogee Therapeutics in Q4 2024 and held it in 2 quarters.
  • Neo Ivy Capital Management's Apogee Therapeutics position peaked at $1.75M in Q4 2024.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.